Trainee Product Management Maternal Infant Care - MIC, w/m/d
About the job
- A completed vocational qualification or degree in nursing, healthcare, medical technology, medicine, business administration, or a comparable field.
- Very good German and English language skills.
- Support the product-management team in the Maternal Infant Care segment and contribute to selected tasks and projects.
- Research, prepare, and analyze market, customer, and competitor information to support the assessment of market opportunities and trends.
- Assist with preparing product and marketing activities, including presentations, market information, and relevant materials.
- Prepare and document product and customer information and ensure that it remains current in the relevant systems.
- Assist with preparing forecasts, reports, and analyses and prepare relevant key performance indicators according to specified methods.
- Contribute to product launches and product enhancements, particularly by preparing and coordinating defined activities with internal functions.
- Support the management of customer and clinical contacts and systematically prepare information from customer interactions.
- Collaborate with internal interfaces such as Sales, Marketing, Service, Finance, and Operations and coordinate the implementation of defined tasks.
- Gradually assume responsibility for defined tasks and projects as part of the trainee program and learn the relevant product-management processes and methods.
- Initial practical experience in healthcare, medical technology, product management, sales, or marketing.
- Interest in Maternal Infant Care, clinical applications, and medical products.
- Interest in market, customer, and competitor analyses.
- An analytical and structured working style, with the ability to present complex information clearly.
- Good communication and teamwork skills and confidence when interacting with internal and external contacts.
- Initiative, willingness to learn, and interest in developing in product management.
About the company
GE Healthcare Systems provides medical technologies and digital infrastructure to improve diagnosis, treatment, and monitoring of patients. Its products include imaging systems, mobile diagnostic devices, patient monitoring tools, and healthcare IT software that work together as hardware, software, and services to support hospitals, clinics, and researchers. The company differentiates itself with a large, integrated ecosystem, strong focus on AI analytics, and a global service network backed by substantial R&D investment. Its goal is to improve patient outcomes and the efficiency of healthcare delivery by enabling accurate diagnoses, effective treatments, and scaled operations.
Company Size
1-10
Company Stage
IPO
Headquarters
Chicago, Illinois
Founded
1892
Get referred to GE Healthcare
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 orders rose 11.1%, and backlog hit a record $23.9 billion.
- Duke Health and Queen's Health Systems will pilot CareIntellect for Operations in 2026.
- AsiaMedic deployed MR31 in Singapore, proving international demand for GE's deep-learning MRI tools.
What critics are saying
- Memorial Sloan Kettering sued GE HealthCare on June 1, 2026, over MotionFree patents.
- Patient Care Solutions revenue fell 13.5% in Q2 2026, and management reviews a sale.
- CFO Jay Saccaro resigned July 21, 2026, weakening execution during a segment turnaround.
What makes GE Healthcare unique
- GE HealthCare's Photonova Spectra won FDA, Japan, and CE clearance in 2026.
- CareIntellect for Operations embeds proprietary AI into hospital workflows, not generic dashboards.
- Vivid Explorer 1, Advanced 1, and Focus 1 cover premium-to-midmarket cardiac imaging.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
401(k) Retirement Plan
401(k) Company Match
Tuition Reimbursement
Relocation Assistance
Company News
AsiaMedic has become the first site in ASEAN to implement MR31, GE HealthCare's latest generation MRI platform featuring deep learning technology. The Singapore-based imaging centre is among the earliest adopters in Asia Pacific. MR31 incorporates deep learning technologies that reduce scan times and enable detailed examinations across neurological, musculoskeletal and nerve imaging. Sonic DL for 3D delivers up to 12 times scan acceleration, reducing examination times across brain, spine, orthopaedic and body scans. The platform also supports high-quality prostate MRI imaging. AIR Recon DL Phase Correction provides improved visualisation of clinically significant lesions, whilst high-resolution T2-weighted imaging aids lesion localisation for prostate fusion biopsy planning. Shorter scan times mean reduced patient time in scanners and may help decrease repeat examinations caused by movement.
GE HealthCare Technologies announced a 14% dividend increase for the third quarter of 2026. The company's board declared a cash dividend of $0.04 per share, up from the previous quarter. The dividend will be paid on 13 November 2026 to shareholders of record as of 23 October 2026. GE HealthCare is a global healthcare solutions provider specialising in medical technology, pharmaceutical diagnostics, and AI-enabled software solutions. The company operates a $20.6 billion business with approximately 54,000 employees worldwide, serving the healthcare industry through its Advanced Imaging Solutions, Pharmaceutical Diagnostics, and Patient Care Solutions segments.
GE HealthCare has launched CareIntellect for Operations, an AI-powered software application that helps health systems forecast capacity constraints up to 72 hours ahead. The solution analyses hundreds of patient and operational data points to predict bottlenecks and recommend actions to optimise capacity and throughput. The Queen's Health Systems and Duke Health will be the first to implement the application. It uses two proprietary AI models: the Pressure Forecast model, which predicts resource constraints across hospitals and departments, and the Estimated Day of Discharge model, which predicts when patients will be discharged. The tool addresses operational challenges as US inpatient volumes rose 5.3% in 2025, requiring health systems to manage increased demand whilst facing staffing shortages and rising costs.
GE HealthCare has received CE mark approval for its Photonova Spectra photon-counting computed tomography system, enabling commercial sales in markets recognising CE marking. The clearance follows US Food and Drug Administration approval and Japanese regulatory clearance in March 2026. The system uses GE HealthCare's Deep Silicon detector technology to deliver ultra-high definition spectral and spatial imaging. It processes data volumes up to 50 times greater than conventional CT systems, utilising Nvidia's accelerated computing platform. Clinical collaborations are underway at UZ Brussel in Belgium and Rigshospitalet in Denmark to evaluate the system across cardiology, neurology, oncology and musculoskeletal imaging. The CE mark follows more than $5 billion in innovation investment by GE HealthCare.
Vertex Pharmaceuticals has emerged as a standout S&P 500 stock, according to StockStory's analysis. The company, which focuses on developing transformative medicines for serious diseases including cystic fibrosis and sickle cell disease, boasts a market capitalisation of $137.3 billion. Meanwhile, StockStory recommends avoiding two large-cap stocks. GE HealthCare, spun off from General Electric in 2023, faces concerns over stagnant organic revenue growth and declining operating margins. The medical equipment provider has a market cap of $32.4 billion. Wells Fargo also made the avoid list. The diversified financial services company, with a $262.2 billion market cap, has seen its net interest margin shrink by 33.6 basis points over two years, suggesting increased competition or declining loan profitability.